Business Description
![Travere Therapeutics Inc Travere Therapeutics Inc logo](https://static.gurufocus.com/logos/0C00006JE0.png?14)
Travere Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US89422G1076
Share Class Description:
TVTX: Ordinary SharesDescription
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.09 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 5.45 | |||||
Debt-to-EBITDA | -1.17 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.14 | |||||
Beneish M-Score | -1.29 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -22.3 | |||||
3-Year EBITDA Growth Rate | -12.9 | |||||
3-Year EPS without NRI Growth Rate | -44 | |||||
3-Year FCF Growth Rate | -8.3 | |||||
3-Year Book Growth Rate | -13 | |||||
Future 3-5Y Total Revenue Growth Rate | 26.1 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.96 | |||||
9-Day RSI | 57.37 | |||||
14-Day RSI | 58.61 | |||||
6-1 Month Momentum % | -15.16 | |||||
12-1 Month Momentum % | -50.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.78 | |||||
Quick Ratio | 2.75 | |||||
Cash Ratio | 2.55 | |||||
Days Inventory | 470.1 | |||||
Days Sales Outstanding | 40.01 | |||||
Days Payable | 935.47 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13 | |||||
Shareholder Yield % | 0.4 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 94.9 | |||||
Operating Margin % | -218.39 | |||||
Net Margin % | -87.94 | |||||
FCF Margin % | -184.84 | |||||
ROE % | -93.65 | |||||
ROA % | -21.04 | |||||
ROIC % | -177.03 | |||||
ROC (Joel Greenblatt) % | -1445.69 | |||||
ROCE % | -63.09 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.31 | |||||
PB Ratio | 8.16 | |||||
EV-to-EBIT | -1.46 | |||||
EV-to-EBITDA | -1.64 | |||||
EV-to-Revenue | 3.1 | |||||
EV-to-Forward-Revenue | 2.69 | |||||
EV-to-FCF | -1.68 | |||||
Price-to-Median-PS-Value | 0.53 | |||||
Earnings Yield (Greenblatt) % | -68.49 | |||||
FCF Yield % | -56.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TVTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Travere Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 183.225 | ||
EPS (TTM) ($) | -2.1 | ||
Beta | 0.86 | ||
Volatility % | 85.61 | ||
14-Day RSI | 58.61 | ||
14-Day ATR ($) | 0.423869 | ||
20-Day SMA ($) | 7.589 | ||
12-1 Month Momentum % | -50.35 | ||
52-Week Range ($) | 5.12 - 17.5699 | ||
Shares Outstanding (Mil) | 76.13 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Travere Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Travere Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Travere Therapeutics Inc Frequently Asked Questions
What is Travere Therapeutics Inc(TVTX)'s stock price today?
The current price of TVTX is $7.94. The 52 week high of TVTX is $17.57 and 52 week low is $5.12.
When is next earnings date of Travere Therapeutics Inc(TVTX)?
The next earnings date of Travere Therapeutics Inc(TVTX) is 2024-08-02 Est..
Does Travere Therapeutics Inc(TVTX) pay dividends? If so, how much?
Travere Therapeutics Inc(TVTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |